Table 2.
COVID-19 frequencies by patient cohort after 1–1 propensity score matching.
| Patient cohort | Patients, N | Total control, N | Treated, N | COVID-19 by control, N (%) | COVID-19 by treated, N (%) |
|---|---|---|---|---|---|
| Vitamin D2 | |||||
| Full patient cohort | |||||
| COVID-19 | 66,432 | 33,216 | 33,216 | 987 (2.97%) | 716 (2.16%) |
| COVID-19 ending in mortality within 30-days | 66,432 | 33,216 | 33,216 | 86 (0.26%) | 65 (0.20%) |
| Vitamin D3 | |||||
| Full patient cohort | |||||
| COVID-19 | 398,996 | 199,498 | 199,498 | 6591 (3.30%) | 5315 (2.66%) |
| COVID-19 ending in mortality within 30-days | 398,996 | 199,498 | 199,498 | 689 (0.35%) | 462 (0.23%) |
| Male cohort | |||||
| COVID-19 | 359,081 | 179,720 | 179,361 | 6008 (3.34%) | 4858 (2.71%) |
| Female cohort | |||||
| COVID-19 | 39,915 | 19,778 | 20,137 | 583 (2.95%) | 457 (2.27%) |
| Black cohort | |||||
| COVID-19 | 71,071 | 36,020 | 35,051 | 1295 (3.59%) | 900 (2.57%) |
| White cohort | |||||
| COVID-19 | 283,248 | 141,229 | 142,019 | 4571 (3.24%) | 3828 (2.70%) |
| 0–19 vitamin D level cohort | |||||
| COVID-19 | 69,067 | 29,324 | 39,743 | 994 (3.39%) | 956 (2.41%) |
| 20–39 vitamin D level cohort | |||||
| COVID-19 | 228,093 | 112,997 | 115,096 | 3621 (3.20%) | 3023 (2.63%) |
| 40 + vitamin D level cohort | |||||
| COVID-19 | 101,836 | 57,177 | 44,659 | 1976 (3.46%) | 1336 (2.99%) |